JPMorgan raised the firm’s price target on Edgewise Therapeutics to $30 from $27 and keeps an Overweight rating on the shares following a model update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- TipRanks ‘Perfect 10’ List: 3 Stocks that Analysts Rate a Strong Buy
- Edgewise Therapeutics added to Best Ideas List at Wedbush
- Edgewise Therapeutics participates in a conference call with JPMorgan
- Edgewise Therapeutics management to meet with Piper Sandler
- Edgewise Therapeutics initiated with Not Rated at Goldman Sachs